Episode
Episode 72. frontMIND Trial in DLBCL with Dr. Charles Herbaux
- Podcast
- Blood Cancer Talks
- Published
- Jun 21, 2026
- Duration seconds
- 2462
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/e589e613
Actions
POST https://stenobird.com/v1/public/podcasts/blood-cancer-talks-5570002/episodes/episode-72-frontmind-trial-in-dlbcl-with-dr-charles-herbaux/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-cancer-talks-5570002/episode-72-frontmind-trial-in-dlbcl-with-dr-charles-herbaux.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Episode Overview For the second time in two decades, a phase 3 trial has shown a statistically significant improvement over R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). In this episode, Eddie, Raj, and Ashwin sit down with Professor Charles Herbaux to unpack the data, debate the clinical implications, and ask the question that's on every hematologist's mind: is this enough to change practice? Background: Setting the Stage for Tafasitamab Before diving into frontMIND, the episode provides context on tafasitamab , a CD19-targeting monoclonal antibody L-MIND (Phase 2 — relapsed/refractory DLBCL): 81 patients with R/R DLBCL ORR 58%, complete response rate 41% Established activity of tafasitamab + lenalidomide in the relapsed setting https://pubmed.ncbi.nlm.nih.gov/32511983/ First-MIND (Phase 1b — frontline DLBCL, IPI 2–5): 66 patients randomized: tafa-R-CHOP (n=33) vs. tafa-len-R-CHOP (n=33) ORR: 75.8% vs. 81.8%, respectively Serious treatment-emergent adverse events: 42.4% vs. 51.5% Provided the signal (and the safety caution) to move to phase 3 https://pubmed.ncbi.nlm.nih.gov/37369099/ The frontMIND Trial Design: Phase 3, double-blind, placebo-controlled randomized trial Intervention: R-CHOP + tafasitamab (12 mg/kg IV days 1, 8, 15 per cycle) + lenalidomide (25 mg/day, days 1–10 per cycle) Control: R-CHOP + placebos GCSF mandatory (given double-blind design); VTE prophylaxis (heparin or aspirin) mandatory given lenalidomide Enrollment: May 2021 – March 2023; 899 patients randomized Primary endpoint: Investigator-assessed progression-free survival (PFS) Patient Population: Age 18–80; DLBCL or high-grade B-cell lymphoma, IPI 3–5 Median age: 65 years 96% advanced stage; 54% bulky disease; 31% ECOG PS 2; 82% elevated LDH 55% IPI 3 / aaIPI 2; 43% IPI 4–5 /…